[ad_1]

TORONTO, July 25, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a international leader in specialized, study-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its prevalent shares are anticipated to commence trading on the Toronto Stock Exchange (“TSX”) on Monday, July 29, 2019 below the symbol “LABS”.  At that time, MediPharm Labs’ prevalent shares will be voluntarily delisted from the TSX Venture Exchange.

A market place open ceremony with MediPharm Labs will be announced.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-grade cannabis oil and concentrates and sophisticated derivative goods using cGMP (existing Great Manufacturing Practices) made facility and ISO regular constructed clean rooms. MediPharm Labs has invested in an professional, study-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with five major extraction lines getting 300,000 KG of annual processing capacity to provide pure, secure and precisely-dosed cannabis goods for its consumers.  Through the Company’s wholesale, private and white label platform, MediPharm Labs formulates, processes, packages and distributes active pharmaceutical components and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a international leader, MediPharm Labs’ completed its very first industrial export to Australia in June 2019 and is nearing completion of its Australian extraction facility anticipated in 2019 with 75,000 KG of annual processing capacity.

For additional facts, please make contact with: 
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 216
E mail: [email protected]
Web site: www.medipharmlabs.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION Solutions PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS Duty FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE Concerning FORWARD-Searching Data:

This news release consists of “forward-seeking information” and “forward-seeking statements” (collectively, “forward-seeking statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical reality, are forward-seeking statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that requires discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or efficiency (normally but not normally utilizing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or outcomes “may” or “could”, “would”, “might” or “will” be taken to happen or be accomplished) are not statements of historical reality and could be forward-seeking statements. In this news release, forward-seeking statements relate to, amongst other issues, the commencement of listing on the TSX and the completion and processing capacity of the Australian facility. Forward-seeking statements are necessarily primarily based upon a quantity of estimates and assumptions that, even though thought of affordable, are topic to identified and unknown dangers, uncertainties, and other variables which could lead to the actual outcomes and future events to differ materially from these expressed or implied by such forward-seeking statements. Such variables include things like, but are not restricted to: common business enterprise, financial, competitive, political and social uncertainties the inability of MediPharm Labs to get sufficient financing the delay or failure to obtain regulatory approvals and other variables discussed in MediPharm Labs’ filings, obtainable on the SEDAR web site at www.sedar.com. There can be no assurance that such statements will prove to be precise, as actual outcomes and future events could differ materially from these anticipated in such statements. Accordingly, readers ought to not spot undue reliance on the forward-seeking statements and facts contained in this news release. Except as expected by law, MediPharm Labs assumes no obligation to update the forward-seeking statements of beliefs, opinions, projections, or other variables, ought to they modify.

Primary Logo



[ad_2]